Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

ACTIVE NOT RECRUITING Phase 3

The Budesonide in Babies (BiB) Trial

NCT04545866 · View on ClinicalTrials.gov ↗

Study Summary

This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to determine whether early intratracheal administration of a combination of budesonide with surfactant, as compared to surfactant alone, will reduce the incidence of physiologic bronchopulmonary dysplasia (BPD) or death by 36 weeks' post-menstrual age in extremely preterm infants.

Interventions

  • DRUG budesonide (Pulmicort nebulizing suspension).
  • DRUG surfactant (poractant alfa;Curosurf)

Study Locations (19)

Ohio

  • Cincinnati Children's Medical Center — Cincinnati
  • Case Western Reserve University, Rainbow Babies and Children's Hospital — Cleveland
  • Research Institute at Nationwide Children's Hospital — Columbus

California

  • Stanford University — Palo Alto
  • Sharp Mary Birch Hospital for Women & Newborns — San Diego

North Carolina

  • RTI International — Durham
  • Duke University — Durham

Texas

  • University of Texas Southwestern Medical Center at Dallas — Dallas
  • University of Texas Health Science Center at Houston — Houston

Alabama

  • University of Alabama — Birmingham

Georgia

  • Emory University — Atlanta

Illinois

  • Northwestern Lurie Children's Hospital of Chicago — Chicago

Iowa

  • University of Iowa — Iowa City

Trial Details

FieldValue
Enrollment Target 642 participants
Start Date 2021-04-01
Est. Completion 2026-12-17
Phase Phase 3

Sponsor

NICHD Neonatal Research Network

44 total trials

Interested in This Trial?

Always speak with your doctor before enrolling in a clinical trial.

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT04545866

The ClinicalTrials.gov registry entry for NCT04545866 describes a study currently listed as active not recruiting. It is categorized as Phase 3, which is the standard way researchers label where a study sits along the investigational pathway from early safety work through later efficacy and post-marketing evaluation. The registered enrollment target is 642 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is NICHD Neonatal Research Network, which has 44 total studies on file at ClinicalTrials.gov, and sponsors are the parties responsible for study design, oversight, and regulatory filings.

The record links to 4 conditions, with Respiratory Distress Syndrome appearing as the primary indexed condition, and to 2 interventions — of which budesonide (Pulmicort nebulizing suspension). is the first listed. Interventions can include drugs, devices, procedures, behavioral programs, or observational arms, and each is tracked as a separate registry field so that downstream queries can filter accurately. When a trial lists multiple interventions, it usually reflects a multi-arm design or a comparison protocol rather than a single treatment being tested in isolation. The brief summary published in the registry is the clearest source of protocol intent and should be read before drawing conclusions from any sidebar tags.

Geographic footprint matters for practical reasons: NCT04545866 reports 19 study locations spanning 14 distinct geographic areas — top geographies include Ohio, California, North Carolina. A larger site network tends to correlate with broader recruitment capacity, but it does not imply anything about study quality, and site-level enrollment status can diverge from the overall registry status shown above. Every data point on this page comes from the public ClinicalTrials.gov dataset and is reproduced here for reference only; it is not a medical recommendation, an endorsement of the sponsor, or an invitation to enroll. Verify current status, eligibility criteria, and contact details directly at ClinicalTrials.gov, and discuss any participation decision with your own healthcare provider.

Frequently Asked Questions

What is clinical trial NCT04545866 about?

NCT04545866 is a clinical study titled "The Budesonide in Babies (BiB) Trial". This is a Phase 3, randomized, masked, active-controlled, multicenter trial designed to determine whether early intratracheal administration of a combination of budesonide with surfactant, as compared to surfactant alone, will reduce the incidence of physiologic bronchopulmonary dysplasia (BPD) or d...

What is the current status of trial NCT04545866?

This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 642 participants. The study started on 2021-04-01. Estimated completion is 2026-12-17.

What conditions does trial NCT04545866 study?

This clinical trial studies the following conditions: Respiratory Distress Syndrome, Bronchopulmonary Dysplasia (BPD), Prematurity; Extreme, Neonatal. These conditions were identified from the trial registry and reflect the primary focus areas of the research.

What interventions are being tested in trial NCT04545866?

The interventions under investigation include: budesonide (Pulmicort nebulizing suspension). (DRUG), surfactant (poractant alfa;Curosurf) (DRUG). Each intervention is being evaluated for safety and efficacy as part of this clinical study.

Who is sponsoring clinical trial NCT04545866?

This trial is sponsored by NICHD Neonatal Research Network, which has 44 total clinical trials registered on ClinicalTrials.gov. The sponsor is responsible for the study's design, funding, and regulatory compliance.

Where is trial NCT04545866 being conducted?

This trial has 19 study locations across Alabama, California, Georgia, Illinois, Iowa. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Related

Data sourced from official U.S. government datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial